Thomas Trimarchi - 16 Aug 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: President and CFO
Issuer ticker: BBIO
Reported as of: 16 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 18:02:40 UTC
Prior SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Will Solis, Attorney-in-Fact

Key filing fact

Thomas Trimarchi filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 18 Aug 2026.

Key facts

This page summarizes Thomas Trimarchi's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 18:02.

Change

Previous filing in this sequence was filed on 19 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002030813 Primary reporting owner

Trimarchi Thomas

Relationship: President and CFO
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Will Solis, Attorney-in-Fact
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Tax liability

Transaction value
Shares: -22,781
Change %: -6.3%
Price: $79.86^*
Shares after: 336,529
Date: 16 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,194 shares of Common Stock underlying the Reporting Person's RSUs.

Footnote F2

Includes 116 shares of the Issuer's Common Stock acquired by the Reporting Person on August 14, 2026 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.